Ninety One UK Ltd Acquires Shares of 9,458 Becton, Dickinson and Company $BDX

Ninety One UK Ltd bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,458 shares of the medical instruments supplier’s stock, valued at approximately $1,629,000.

Several other large investors have also modified their holdings of BDX. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Versant Capital Management Inc lifted its stake in Becton, Dickinson and Company by 27.4% during the first quarter. Versant Capital Management Inc now owns 265 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 57 shares during the last quarter. NBC Securities Inc. acquired a new position in Becton, Dickinson and Company in the first quarter worth $102,000. Merit Financial Group LLC increased its stake in Becton, Dickinson and Company by 54.3% during the first quarter. Merit Financial Group LLC now owns 5,846 shares of the medical instruments supplier’s stock valued at $1,339,000 after purchasing an additional 2,058 shares during the last quarter. Finally, Whipplewood Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 67.9% during the first quarter. Whipplewood Advisors LLC now owns 880 shares of the medical instruments supplier’s stock worth $202,000 after purchasing an additional 356 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock worth $562,036 over the last 90 days. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price for the company. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Morgan Stanley upped their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $190.90 on Thursday. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a market cap of $54.72 billion, a PE ratio of 34.33, a P/E/G ratio of 1.51 and a beta of 0.25. The stock has a 50 day simple moving average of $188.71 and a 200-day simple moving average of $188.20. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the previous year, the business earned $3.50 EPS. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.